Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar erosion expected for rituximab, the patient share and sales leader of 2015 in the NHL space, as well as the generic erosion of lenalidomide (and to a lesser extent bendamustine), will temper the overall growth of this market. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with experts and 213 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence for FL (including transformed FL), CLL/SLL, DLBCL, and MCL.
Population segments in market forecast: First line, second line, and third line for FL, CLL/SLL, DLBCL, and MCL.
Emerging therapies: Phase I and II: 39 drugs; Phase III: 6 drugs; preregistration: 0 drugs; registered: 0 drugs.